AASLD 2015: Gilead Leads Race To Shorter, Pan-Genotypic HCV Treatments
This article was originally published in Scrip
Executive Summary
Gilead Sciences has led the race to market with ribavirin- and interferon-free therapies that cure most people with the hepatitis C virus (HCV), but Merck & Co. Inc. is gaining ground in the sprint toward shorter-term, pan-genotypic, two- and three-drug regimens, with AbbVie Inc. on their heels with its own dual therapy that also may eliminate HCV infection in some of the most difficult to treat patients.